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Abstract
Although an androgen deprivation therapy plus docetaxel regimen was shown to extend the survival of some
patients with metastatic hormone-sensitive prostate cancer compared with androgen deprivation therapy
alone, currently, there is no report in the literature investigating the impact of upfront docetaxel on subsequent
first-line abiraterone acetate or enzalutamide for metastatic castration-resistant prostate cancer. This study
showed that their activity is maintained regardless of previous use of docetaxel for metastatic hormone-
sensitive prostate cancer. These findings can aid treatment decision-making.
Background: The CHAARTED (ChemoHormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive
Disease in Prostate Cancer) and STAMPEDE (Systemic Therapy in Advancing orMetastatic ProstateCancer: Evaluation of
DrugEfficacy) trials showed that the addition of docetaxel (D) to androgen deprivation therapy (ADT) prolonged longevity of
men with metastatic hormone-sensitive prostate cancer (mHSPC). However, the impact of upfront D on subsequent
therapies is still unexplored. As abiraterone acetate (AA) and enzalutamide (E) are the most commonly used first-line
treatment for metastatic castration-resistant prostate cancer (mCRPC), we aimed to assess whether they maintained
their efficacy after ADTþD versus ADT alone. Patients and Methods: A cohort of patients with mCRPC treated between
2014 and 2017 with first-line AA or E for mCRPC was identified from 3 hospitals’ institutional review board-approved
databases. Patients were classified by use of D for mHSPC. This time frame was chosen as ADTþD became a valid
therapeutic option for mHSPC in 2014, and it inherently entailed a short follow-up time on AA/E. The endpoints included
overall survival from ADT start, overall survival fromAA/E start, and time to AA/E start from ADT start. Differences between
groups were assessed using the log-rank test. Results: Of the 102 patients with mCRPC identified, 50 (49%) had previ-
ously received ADT alone, while 52 (51%) had ADTþD. No statistically significant difference in any of the evaluated out-
comes was observed between the 2 cohorts. Yet, deaths in the ADTþD group were 12 versus 21 in the ADT alone, after a
median follow-up of 24.4 and 29.8 months, respectively. Conclusion: In a cohort of ADT/ADTþD-treated patients with
mCRPC with short times to first-line AA/E and follow-up, the efficacy of AA/E is similar regardless of previous use of D.
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Introduction appropriate sequence of drugs for a given patient after failure of the
Until recently, androgen deprivation therapy (ADT) by surgical
or medical castration has been the standard-of-care for metastatic
hormone-sensitive prostate cancer (mHSPC).1 Upon progression,
prostate cancer is termed castration-resistant, and chemotherapy and
second-generation androgen receptor (AR) targeting agents, such as
abiraterone acetate (AA) and enzalutamide (E), proven in clinical
trials to increase longevity of men with metastatic castration-
resistant prostate cancer (mCRPC), are used in patients deemed
fit.2-4 In this regard, a recent analysis of prescriptions in the United
States reported that AA and E are the preferred (76%) first-line
therapy for men with mCRPC.5
Recently, 2 new regimens combining ADT with docetaxel (D) and
AA, respectively, have shown a survival advantage compared with
ADT alone and have become new valid therapeutic options for the
patient with mHSPC.6-9 Particularly, the chemohormonal combina-
tion showed a clear benefit for men with mHSPC with high-volume
disease compared with ADT alone and has been introduced in the
treatment paradigm of mHSPC in 2014. However, to date, there is no
report in the literature evaluating the impact of early D on subsequent
first-line AA or E for mCRPC, and an optimal sequence of drugs after
progression on ADTþD does not exist. The E3805 CHAARTED
(ChemoHormonal Therapy Versus Androgen Ablation Randomized
Trial for Extensive Disease in Prostate Cancer) investigators demon-
strated that the addition of D to ADT versus ADT alone prolonged
time to CRPC (19.4 vs. 11.7 months; hazard ratio [HR], 0.61; 95%
confidence interval [CI], 0.52-0.73; P < .0001), and time to clinical
progression (33.0 vs. 19.8 months; HR, 0.62; 95% CI, 0.51-0.75;
P< .0001), respectively.6 Based on the similar HR data, we postulated
that first-line AA or E for mCRPC at least maintained efficacy after
ADTþD versus ADT alone. The biological rationale for this hy-
pothesis is that early D debulks AR-independent tumor cells that
would otherwise thrive under the positive selective pressure exerted by
ADT alone and thus enhances the efficacy of AR-targeting AA or E as
first-line treatment for mCRPC.6,10 Determining the impact of early
D for mHSPC on subsequent AA/E therapy would greatly aid treat-
ment decision-making and provide useful data to delineate the mostTable 1 Patient Characteristics According to the Use of D in Additi





Missing data 49 (48)
Prior local therapy 30 (29)





Median follow-up, mos (95% CI) 26.4 (24.0-29.9)
Abbreviations: AA ¼ Abiraterone acetate; ADT ¼ androgen deprivation therapy; CI ¼ confidence inter
mos ¼ months; N ¼ number.chemohormonal regimen. Therefore, in this report, we aimed to
evaluate the outcomes of first-line AA or E treatment for patients with
mCRPC selected from 3 hospitals’ databases and classified by use of D
for mHSPC.
Patients and Methods
From the Dana-Farber Cancer Institute of Boston, the St Vin-
cent’s Hospital of Sydney, and the Tom Baker Cancer Centre of
Calgary Institutional Review Board-approved databases, we retro-
spectively identified consecutive patients with histologically
confirmed and radiologically evaluable mCRPC who had initiated
AA or E as first-line treatment for mCRPC between 2014 and
2017. This time frame was selected considering that the chemo-
hormonal regimen was recognized as a valid therapeutic option for
mHSPC in 2014. Patients were excluded if they had received AA or
E for any earlier stage of disease or had been given any other agent as
first-line treatment for mCRPC. The final cohort was classified by
previous use of D for mHSPC into 2 groups: ADTþD and ADT
alone. The primary endpoints of the study were overall survival
(OS) from ADT start and OS from AA/E start, defined as time from
ADT for mHSPC and time from first-line AA/E for mCRPC start,
respectively, to death from any cause or censored at last follow-up
visit. Time to AA/E start, defined as the interval from ADT
commencement to initiation of first-line AA/E for mCRPC, was the
secondary endpoint. The Kaplan-Meier method was used to esti-
mate the distributions of the endpoints, including median time-to-
event and its 95% CI, and the log-rank test was used to compare
time-to-event distributions between the 2 groups. Time of meta-
static disease presentation, whether after prior definitive local ther-
apy or newly diagnosed (de novo), biopsy Gleason score, and
follow-up data was collected from medical records.
Results
Overall, 102 patients with mCRPC were eligible for this analysis.
Fifty-two (51%) had received ADTþD and 50 (49%) ADT alone,
for mHSPC. Baseline patient characteristics are described inon to ADT for mHSPC
ADT Alone, N [ 50 (%) ADTDD, N [ 52 (%)
1 (2) 0 (0)
1 (2) 14 (27)
23 (46) 14 (27)
25 (50) 24 (46)
15 (30) 15 (29)
35 (70) 37 (71)
24 (48) 27 (52)
23 (46) 25 (48)
3 (6) 0 (0)
29.8 (25.1-31.4) 24.4 (21.7-27.1)
val; D ¼ docetaxel; E ¼ enzalutamide; mHSPC ¼ metastatic hormone sensitive prostate cancer;
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mos (95% CI) P Value
Time to AA/E Start,
mos (95% CI) P Value
Median OS
From AA/E Start,
mos (95% CI) P Value
ADT 50 (49) 21 (29.8) 33.5 (22.4 to NR) .2047 11.0 (8.5-13.7) .7265 17.3 (13.7 to NR) .6514
ADTþD 52 (51) 12 (24.4) NR (NR to NR) 12.8 (11.1-15.7) NR (13.1 to NR)
Abbreviations: AA ¼ Abiraterone acetate; ADT ¼ androgen deprivation therapy; CI ¼ confidence interval; D ¼ docetaxel; E ¼ enzalutamide; mos ¼ months; No ¼ number; NR ¼ not yet reached;
OS ¼ overall survival.
First-line Abiraterone Acetate or Enzalutamide for mCRPC After ADT With or Without Docetaxel
132 -Table 1. Despite randomization not being part of the study design,
the 2 cohorts were well-balanced in terms of prior local therapy/de
novo, median follow-up, and distributions of AA and E, which were
similar also in the total population (50% vs. 47%, respectively).
Most patients (71%) had de novo disease, and of the 53 with
available data, 37 had biopsy Gleason score  8. Median follow-up
was only 26.4 months (95% CI, 24.0-29.9 months) owing to the
chosen eligibility time window. For the same reason, time to AA/E
start was also short at 11.0 months (95% CI, 8.5-13.7 months) for
the ADT-alone cohort and 12.8 months (95% CI, 11.1-15.7
months) for the ADTþD cohort (Table 2). In this regard, no sta-
tistically significant difference was observed in time to AA/E start
between the 2 study groups (P ¼ .7265). Furthermore, the 2 co-
horts did not show any significant difference in OS from ADT start
(P¼ .2047) or in OS from AA/E start (P¼ .6514) (Table 2). In the
ADTþD group, neither the median survival from ADT start (not
yet reached [NR]; 95% CI, NR to NR) nor the median OS from
AA/E start (NR; 95% CI, 13.1 to NR) had been reached at the time
of the analysis. The Kaplan-Meier estimates confirm these findings,
showing the 2 study groups with similar survival and time to AA/E
start curves, respectively, and not-reached median survivals for the
chemohormonal cohort (Figure 1). Notably, OS from ADT start in
the ADT alone group at 33.5 months (95% CI, 22.4 months to
NR) was in line with that of patients with poor prognostic factors,Figure 1 Kaplan-Meier Estimates of OS From ADT Start (A), OS Fro
Abbreviations: AA ¼ Abiraterone acetate; ADT ¼ androgen deprivation therapy; E ¼ enzalutamide;
Clinical Genitourinary Cancer April 2018such as high-volume and de novo metastatic disease, as noted in the
CHAARTED, LATITUDE (Study of Abiraterone Acetate Plus
Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT)
versus ADT Alone in Newly Diagnosed Participants With High-
Risk, Metastatic Hormone-Naive Prostate Cancer), and GETUG
(Genitourinary Group)-AFU (French Association of Urology)15
trials.8,11,12 In this respect, prostate-cancer deaths in the ADT-alone
group were 21 versus 12 in the ADTþD group, after a median
follow-up of 29.8 and 24.4 months, respectively (Table 2).
Discussion
Although the addition of D to ADT proved to be significantly
beneficial for men with mHSPC,6,7 the impact of upfront D on
later therapies has not been yet investigated, and an optimal treat-
ment sequence for mCRPC has not been defined by well-powered
prospective trials, even for patients receiving D in the standard
setting. In a recent analysis, second-generation hormonal agents AA
and E have been reported as the most commonly administered first-
line treatment for men in the United States with mCRPC.5 To our
knowledge, this retrospective study is the first to explore the in-
fluence of early D on the clinical efficacy of subsequent first-line AA
or E for mCRPC, using contemporaneous cohorts of ADTþD and
ADT-alone pretreated men with mCRPC. It has been theorized
that early chemotherapy disposes of AR-independent tumor clones;m AA/E Start (B), and Time to AA/E Start (C)
OS ¼ overall survival.
Edoardo Francini et alhence, favoring efficacy of AR targeting AA/E as first-line treatment
for mCRPC.6,10 On the other hand, a few in vivo and in vitro
studies observed cross-resistance between D for mCRPC, and
subsequent AA or E and partly attributed it to the partially over-
lapping mechanisms of action of these drugs, which interfere with
AR signaling pathway and inhibit AR nuclear translocation.13-15 In
the present study, D is used for the hormone-sensitive disease, but
the treatment sequence is the same; hence, cross-resistance could
arise. However, this report showed that first-line AA or E therapy
for mCRPC maintains its activity whether D was used upfront or
not. Specifically, there was no statically significant difference in any
of the explored outcomes. Nonetheless, it should be noted that, in
the ADT-alone group, OS from AA/E start was considerably shorter
at 17.3 months (95% CI, 13.7 months to NR) than observed with
pre-chemotherapy AA and E for mCRPC in the final analyses of
their pivotal trials (34.7 months [95% CI, 32.7-36.8 months] and
35.3 months [95% CI, 32.2 months to NR], respectively).16,17
Furthermore, OS from ADT start was short at 33.5 months
(95% CI, 22.4 months to NR) and consistent with a population
with poor prognostic features.8,11,12 Patients’ baseline characteristics
seem to support this premise, because 71% of the total population
and 70% of the ADT alone cohort had de novo metastatic disease,
and 37 of the 53 patients without missing data and, remarkably, 23
of 25 in the ADT-alone cohort had biopsy Gleason score  8. This
is not surprising given the chosen recruitment time window, which
inevitably determined a short median follow-up and a selection of
patients with short times to AA/E start, which were 29.8 months
(95% CI, 25.1-31.4 months) and 11.0 months (95% CI, 8.5-13.7
months) for the ADT-alone cohort, respectively. The present
analysis is therefore heavily weighted by the early events, which were
very similar in both arms, even in the pivotal studies that, as a
matter of fact, required a longer follow-up for the benefits to be
seen. As such, although the median survivals in the ADTþD group
were not reached at the time of the analysis, there was no statistically
significant difference from the ADT-alone group. Yet prostate
cancer deaths were more numerous in the ADT-alone cohort
compared with the ADTþD cohort (21 vs. 12 after a median
follow-up of 29.8 and 24.4 months, respectively). This finding is
visually highlighted by the Kaplan-Meier estimates of OS from
ADT start, which show a gap between the curves starting after 15
months and quite steadily widening over time in favor of the
combination group (Figure 1A). This also appears to be the case of
OS from AA/E start (Figure 1B). Longer follow-up and possibly
larger samples would be needed to confirm this trend. However,
despite not reaching a statistically significant difference, men treated
with the chemohormonal regimen tended to experience a longer
time to AA/E start (Figure 1C) compared with those treated with
ADT alone. Therefore, considering that the 2 study groups were
well-balanced with respect to the number of patients and the clinical
and treatment characteristics, we could speculate that patients who
received upfront D appear to be faring better with first-line AA or E
for mCRPC than patients who received ADT alone, which is
consistent with our hypothesis. Larger prospective studies with
longer follow-up and better biological and clinical patient charac-
terization would be needed to confidently confirm this hypothesis.
As the chemohormonal regimen is being increasingly adminis-
tered to the population with mHSPC, gathering evidence on themost appropriate sequence of additional treatments after failure of
upfront D has become paramount. To the authors’ knowledge, the
present analysis is the first to provide useful clinical data to address
this issue. Nevertheless, the innate biases of this study, including the
short median follow-up, small sample size, and retrospective nature,
represent limitations that prevent generalization of the results. On
the other hand, interpreted with caution, this data may aid the
physician in treatment decision-making and reassure him on the use
of early D for mHSPC. In fact, our outcomes showed that exposure
to upfront D for mHSPC patients with poor prognostic factors,
such as de novo metastatic presentation, at least does not reduce the
efficacy of later AA/E used as first-line treatment for mCRPC. This
conclusion is supported by the results of the latest post-hoc analysis
of the STAMPEDE (Systemic Therapy in Advancing or Metastatic
Prostate Cancer: Evaluation of Drug Efficacy) trial comparing 2
contemporaneously randomized cohorts of patients treated with
ADTþD and ADTþAA, respectively.18 Despite the limited sta-
tistical power and, similar to our study, a short follow-up
(approximately 4 years), this report showed that the ADT plus
AA significantly extends failure-free survival and progression-free
survival compared with the chemohormonal regimen in the
population with mHSPC. However, OS from randomization did
not differ between the 2 treatment arms. Because most
patients progressing after upfront D received AA or E,18 it would
appear that the activity of first-line AA or E for mCRPC was at
least not diminished by previous use of D, as suggested by our
analysis.
Given the heterogeneity of prostate cancer, we deem it unlikely
that a single sequence of treatments could provide the best benefit/
risk ratio to all patients with mCRPC progressing on early D. An
individualized therapeutic approach that takes into account the
diverse tumor biological and molecular features, patient clinical
characteristics, and prognostic and predictive biomarkers would be
required to maximize survival. However, although the continuous
advances in the knowledge of tumor biology and in the develop-
ment of biotechnologies pave the way towards a future of precision
medicine, clinical reports addressing treatment sequencing questions
can provide the clinician with useful indications to make evidence-
based decisions.
Conclusion
Despite the shortcomings of this analysis, we deem our data
clinically relevant as they suggest that, in a cohort of patients with
short median follow-up and time to AA/E start, first-line AA/E
treatment for mCRPC maintains its efficacy regardless of previous
use of D for mHSPC.
Clinical Practice Points
 AA and E are the most frequently used first-line treatment for
mCRPC.
 In patients with mCRPC, the efficacy of AA/E seems to be
similar regardless of previous use of D for mHSPC.
 Larger prospective studies with longer follow-up and better
biological and clinical patient characterization are warranted to
confirm these findings.
 These results may aid the physician in the treatment decision-
making and reassure him on the use of early D for mHSPC.Clinical Genitourinary Cancer April 2018 - 133
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